Weisberg Cancer Treatment Center

Summary

Weisberg Cancer Treatment Center is a medical facility located in Farmington, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Breast cancer and other specialties. Weisberg Cancer Treatment Center is involved with conducting 185 clinical trials across 255 conditions. There are 27 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Dipenkumar Modi, M.D., and Hirva Mamdani, MD.

Top PIs

Clinical Trials running at Weisberg Cancer Treatment Center

Laryngeal Cancer

Lung Cancer

Throat Cancer

Esophageal cancer

Bladder Cancer

Oropharyngeal Carcinoma

Breast Cancer

Lip and Oral Cavity Cancer

Acute Myeloid Leukemia

Squamous Cell Carcinoma

Radiation Therapy + Cisplatin

for Head and Neck Cancer

This trial is studying if using a specific type of energy treatment alone or with a drug is better for treating patients with advanced head and neck cancer after surgery. The energy treatment kills cancer cells, and the drug helps by stopping their growth or killing them. The drug has been used for many years in the treatment of advanced cancers, including head and neck cancers, and is known for its ability to enhance the effects of the energy treatment.

Recruiting

1 award

Phase 2

19 criteria

Cabozantinib + Nivolumab

for Advanced Skin and Head & Neck Cancers

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.

Recruiting

1 award

Phase 2

BMX-001

for Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.

Recruiting

0 awards

Phase 2

7 criteria